Drug Search Results
More Filters [+]

Etidronic acid

Alternative Names: etidronic acid, etidronate, ethidronate, hdepa, didronel, osteoscan, mpi stannous diphosphonate
Latest Update: 2023-10-26
Latest Update Note: Clinical Trial Update

Product Description

Etidronic Acid is as a member of the family of drugs known as bisphosphonates, etidronate differs from endogenous pyrophosphate in its resistance to enzymatic hydrolysis. This agent adsorbs to hydroxyapatite cells and reduces the number of osteoclasts, thereby inhibiting abnormal bone resorption. Etidronate may also directly stimulate bone formation by osteoblasts. (NCI) (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Etidronic-acid)

Mechanisms of Action: Bone Resorption Inhibitor,Hydroxyapatite Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Canada | Chile | Colombia | Egypt | Germany | Greece | India | Ireland | Italy | Korea | Morocco | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Etidronic acid

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Bone Cancer|Movement Disorders|Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CALCIFADE trial

P2

Active, not recruiting

Movement Disorders

2027-03-20

CTR20200377

P2

Recruiting

Bone Cancer|Prostate Cancer

None

Recent News Events